Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Operating Leases: 2023-2025

Historic Operating Leases for Immunome (IMNM) over the last 2 years, with Sep 2025 value amounting to $4.0 million.

  • Immunome's Operating Leases rose 62.87% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 62.87%. This contributed to the annual value of $4.8 million for FY2024, which is 255.90% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Operating Leases is $4.0 million, which was down 3.11% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Operating Leases registered a high of $4.8 million during Q1 2025, and its lowest value of $1.2 million during Q1 2024.
  • Over the past 3 years, Immunome's median Operating Leases value was $2.5 million (recorded in 2024), while the average stood at $2.9 million.
  • Its Operating Leases has fluctuated over the past 5 years, first dropped by 10.00% in 2024, then soared by 295.52% in 2025.
  • Immunome's Operating Leases (Quarterly) stood at $1.3 million in 2023, then skyrocketed by 255.90% to $4.8 million in 2024, then surged by 62.87% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.1 million for Q2 2025, and $4.8 million during Q1 2025.